These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31333109)

  • 41. Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.
    Liu LS; Li J; Chen XT; Zhang HX; Fu Q; Wang HY; Xiong YY; Liu S; Liu XM; Li JL; Huang M; Wang CX
    Int J Clin Pract Suppl; 2015 May; (183):43-52. PubMed ID: 26177348
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients.
    Włodarczyk Z; Wałaszewski J; Perner F; Vitko S; Ostrowski M; Bachleda P; Kokot F; Klinger M; Szenohradsky P; Studenik P; Navratil P; Asztalos L; Rutkowski B; Nagy KK; Hickey D
    Ann Transplant; 2002; 7(3):28-31. PubMed ID: 12465429
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation.
    Gaynor JJ; Ciancio G; Guerra G; Sageshima J; Roth D; Goldstein MJ; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Ruiz P; Vianna R; Burke GW
    Transpl Int; 2016 Feb; 29(2):216-26. PubMed ID: 26442829
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association Between the Intracellular Tacrolimus Concentration in CD3 + T Lymphocytes and CD14 + Monocytes and Acute Kidney Transplant Rejection.
    Udomkarnjananun S; Francke MI; Dieterich M; van de Velde D; Verhoeven JGHP; Boer K; Clahsen-Van Groningen MC; De Winter BCM; Baan CC; Hesselink DA
    Ther Drug Monit; 2022 Oct; 44(5):625-632. PubMed ID: 35358111
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis.
    Rodríguez-Perálvarez M; Germani G; Darius T; Lerut J; Tsochatzis E; Burroughs AK
    Am J Transplant; 2012 Oct; 12(10):2797-814. PubMed ID: 22703529
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients.
    Tavira B; Coto E; Diaz-Corte C; Alvarez V; López-Larrea C; Ortega F
    Pharmacogenet Genomics; 2013 Aug; 23(8):445-8. PubMed ID: 23778326
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
    Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
    Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term outcome of sirolimus rescue in kidney-pancreas transplantation.
    Rogers J; Ashcraft EE; Baliga PK; Chavin KD; Lin A; Emovon O; Afzal F; Baillie GM; Taber DJ; Alvarez S; Pullatt RC; Rajagopalan PR
    Transplant Proc; 2004 May; 36(4):1058-60. PubMed ID: 15194367
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Graft-implanted, enzyme responsive, tacrolimus-eluting hydrogel enables long-term survival of orthotopic porcine limb vascularized composite allografts: A proof of concept study.
    Fries CA; Lawson SD; Wang LC; Slaughter KV; Vemula PK; Dhayani A; Joshi N; Karp JM; Rickard RF; Gorantla VS; Davis MR
    PLoS One; 2019; 14(1):e0210914. PubMed ID: 30677062
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of immunosuppressive regimen on acute rejection and liver graft function.
    Ziolkowski J; Paczek L; Niewczas M; Senatorski G; Oldakowska-Jedynak U; Wyzgal J; Foroncewicz B; Mucha K; Zegarska J; Nyckowski P; Zieniewicz K; Patkowski W; Krawczyk M; Ziarkiewicz-Wroblewska B; Gornicka B
    Transplant Proc; 2003 Sep; 35(6):2281-3. PubMed ID: 14529915
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of the combination of time-weighted variability of tacrolimus blood level and exposure to low drug levels with graft survival after kidney transplantation.
    Rozen-Zvi B; Schneider S; Lichtenberg S; Green H; Cohen O; Gafter U; Chagnac A; Mor E; Rahamimov R
    Nephrol Dial Transplant; 2017 Feb; 32(2):393-399. PubMed ID: 28025383
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.
    Guethoff S; Meiser BM; Groetzner J; Eifert S; Grinninger C; Ueberfuhr P; Reichart B; Hagl C; Kaczmarek I
    Transplantation; 2013 Feb; 95(4):629-34. PubMed ID: 23423270
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of the Relationship Between Concentrations of Tacrolimus Metabolites, 13-O-Demethyl Tacrolimus and 15-O-Demethyl Tacrolimus, and Clinical and Biochemical Parameters in Kidney Transplant Recipients.
    Zegarska J; Hryniewiecka E; Zochowska D; Samborowska E; Jazwiec R; Maciej K; Nazarewski S; Dadlez M; Paczek L
    Transplant Proc; 2018 Sep; 50(7):2235-2239. PubMed ID: 30177142
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation.
    Tzakis AG; Tryphonopoulos P; Kato T; Nishida S; Levi DM; Madariaga JR; Gaynor JJ; De Faria W; Regev A; Esquenazi V; Weppler D; Ruiz P; Miller J
    Transplantation; 2004 Apr; 77(8):1209-14. PubMed ID: 15114087
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation.
    Elens L; Capron A; Kerckhove VV; Lerut J; Mourad M; Lison D; Wallemacq P; Haufroid V
    Pharmacogenet Genomics; 2007 Oct; 17(10):873-83. PubMed ID: 17885626
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation.
    Aidong W; Zhenjie C; Tong L; Lei Z; Yin W; Shanqi Z; Liping T
    Transplant Proc; 2004 Oct; 36(8):2388-9. PubMed ID: 15561258
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tacrolimus trough levels and level-to-dose ratio in stable renal transplant patients converted to a once-daily regimen.
    Meçule A; Tinti F; Poli L; Bachetoni A; Umbro I; Nofroni I; Lai Q; Pretagostini R; Berloco PB; Mitterhofer AP
    Transplant Proc; 2011 May; 43(4):1024-7. PubMed ID: 21620042
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Volatility of serum creatinine relative to tacrolimus levels predicts kidney transplant rejection.
    Schmid S; Bryce R; Reeder B; Rana M; Pahwa P; Shoker A; Moser MA
    Ann Transplant; 2014 Aug; 19():403-6. PubMed ID: 25123847
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Coadministration of Erythromycin to Increase Tacrolimus Concentrations in Liver Transplant Recipients.
    Chiang LH; Wu TH; Tsai TC; Lee WC
    Transplant Proc; 2019 Jun; 51(5):1439-1441. PubMed ID: 31155178
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients.
    Andrews LM; Li Y; De Winter BCM; Shi YY; Baan CC; Van Gelder T; Hesselink DA
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1225-1236. PubMed ID: 29084469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.